See more : AUTO1 Group SE (AG1.DE) Income Statement Analysis – Financial Results
Complete financial analysis of Protagonist Therapeutics, Inc. (PTGX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Protagonist Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Shanthi Gears Limited (SHANTIGEAR.NS) Income Statement Analysis – Financial Results
- Tainan Enterprises Co.,Ltd (1473.TW) Income Statement Analysis – Financial Results
- Zaptec AS (ZAP.OL) Income Statement Analysis – Financial Results
- Abby, Inc. (ABBY) Income Statement Analysis – Financial Results
- HIVE Blockchain Technologies Ltd. (HIVE) Income Statement Analysis – Financial Results
Protagonist Therapeutics, Inc. (PTGX)
About Protagonist Therapeutics, Inc.
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- specific antagonist peptide that is in Phase II clinical trials for treating inflammatory bowel disease (IBD); and PN-235, an orally delivered interleukin-23 receptor specific antagonist for the treatment of IBD and non-IBD indications. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
---|---|---|---|---|---|---|---|---|---|---|
Revenue | 60.00M | 26.58M | 27.36M | 28.63M | 231.00K | 30.93M | 20.06M | 0.00 | 0.00 | 0.00 |
Cost of Revenue | 0.00 | 1.03M | 2.78M | 0.00 | 0.00 | 0.00 | 0.00 | 317.00K | 247.00K | 0.00 |
Gross Profit | 60.00M | 25.55M | 24.58M | 28.63M | 231.00K | 30.93M | 20.06M | -317.00K | -247.00K | 0.00 |
Gross Profit Ratio | 100.00% | 96.12% | 89.86% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% |
Research & Development | 120.16M | 126.22M | 126.01M | 74.51M | 65.00M | 59.50M | 46.18M | 25.71M | 11.83M | 7.46M |
General & Administrative | 33.49M | 31.74M | 27.20M | 18.64M | 15.75M | 13.70M | 11.78M | 6.96M | 2.96M | 1.86M |
Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A | 33.49M | 31.74M | 27.20M | 18.64M | 15.75M | 13.70M | 11.78M | 6.96M | 2.96M | 1.86M |
Other Expenses | 0.00 | -80.00K | -149.00K | -46.00K | -1.00K | 0.00 | 0.00 | -34.00K | 0.00 | 0.00 |
Operating Expenses | 153.65M | 157.95M | 153.20M | 93.14M | 80.75M | 73.19M | 57.96M | 32.67M | 14.79M | 9.32M |
Cost & Expenses | 153.65M | 157.95M | 153.20M | 93.14M | 80.75M | 73.19M | 57.96M | 32.67M | 14.79M | 9.32M |
Interest Income | 14.90M | 4.06M | 443.00K | 900.00K | 2.81M | 2.57M | 948.00K | 242.00K | 19.00K | 16.00K |
Interest Expense | 0.00 | 0.00 | 0.00 | 598.00K | 169.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Depreciation & Amortization | 3.31M | 1.03M | 2.78M | 789.00K | 703.00K | 527.00K | 406.00K | 317.00K | 247.00K | 258.00K |
EBITDA | -90.34M | -131.37M | -123.07M | -63.66M | -78.31M | -39.20M | -36.55M | -32.35M | -14.55M | -9.06M |
EBITDA Ratio | -150.57% | -494.24% | -458.94% | -222.38% | -33,640.26% | -136.68% | -188.89% | 0.00% | 0.00% | 0.00% |
Operating Income | -93.65M | -131.37M | -125.85M | -64.52M | -80.52M | -42.27M | -37.90M | -32.67M | -14.79M | -9.32M |
Operating Income Ratio | -156.09% | -494.24% | -460.01% | -225.36% | -34,857.58% | -136.68% | -188.89% | 0.00% | 0.00% | 0.00% |
Total Other Income/Expenses | 14.70M | 3.98M | 294.00K | -329.00K | 2.64M | 2.55M | 940.00K | -4.51M | -64.00K | -1.75M |
Income Before Tax | -78.96M | -127.39M | -125.55M | -64.85M | -77.88M | -39.72M | -36.96M | -37.18M | -14.86M | -11.07M |
Income Before Tax Ratio | -131.59% | -479.26% | -458.94% | -226.51% | -33,713.42% | -128.45% | -184.20% | 0.00% | 0.00% | 0.00% |
Income Tax Expense | 0.00 | -3.98M | -2.92M | 1.31M | -691.00K | -799.00K | -406.00K | 4.16M | 64.00K | 1.75M |
Net Income | -78.96M | -123.41M | -122.63M | -66.15M | -77.19M | -38.92M | -36.96M | -37.18M | -14.86M | -11.07M |
Net Income Ratio | -131.59% | -464.29% | -448.25% | -231.07% | -33,414.29% | -125.87% | -184.20% | 0.00% | 0.00% | 0.00% |
EPS | -1.39 | -2.52 | -2.65 | -1.92 | -2.98 | -1.74 | -2.09 | -5.72 | -2.52 | -1.88 |
EPS Diluted | -1.39 | -2.52 | -2.65 | -1.92 | -2.98 | -1.74 | -2.09 | -5.72 | -2.52 | -1.88 |
Weighted Avg Shares Out | 56.76M | 49.04M | 46.32M | 34.40M | 25.89M | 22.36M | 17.69M | 6.50M | 5.88M | 5.88M |
Weighted Avg Shares Out (Dil) | 56.76M | 49.04M | 46.32M | 34.40M | 25.89M | 22.36M | 17.69M | 6.50M | 5.88M | 5.88M |
Wall Street Analysts Believe Protagonist Therapeutics (PTGX) Could Rally 37.16%: Here's is How to Trade
Recent Price Trend in Protagonist Therapeutics (PTGX) is Your Friend, Here's Why
Protagonist Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
New England Journal of Medicine Publishes Results of Positive Randomized Phase 2 REVIVE Trial of Rusfertide in Treatment of Polycythemia Vera
Protagonist Therapeutics Reports Granting of Inducement Awards
New England Journal of Medicine Publishes Efficacy and Safety Data of Targeted Oral Peptide JNJ-2113 in a Phase 2b Moderate-To-Severe Plaque Psoriasis Study
Protagonist (PTGX) Up 14% on Licensing Deal With Takeda
Takeda and Protagonist Therapeutics, Inc. Enter into Worldwide License and Collaboration Agreement for Rusfertide, a Late-Stage Rare Hematology Asset
Protagonist Therapeutics to Participate in Fireside Chat at Guggenheim Healthcare Talks 2024
Protagonist Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
Source: https://incomestatements.info
Category: Stock Reports